Prot # BCX1812-303: A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects with Confirmed or Suspected Influenza Infection

Project: Research project

Project Details

StatusFinished
Effective start/end date9/28/099/27/12

Funding

  • Quintiles, Inc. (BCX1812-303)
  • BioCryst Pharmaceuticals (BCX1812-303)